Edap TMS SA (FOCL)
Nasdaq · Electromedical & Electrotherapeutic Apparatus · Manufacturing · CIK 1041934 · fiscal year ends in Dec
Closing price $4.20 on 30 Oct 2026; 52-week range $1.99 to $6.34.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Market value
- $157.6M
- Cash
- $21.5M
- Debt
- $39.9M
- Shares outstanding
- 37.5M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $70.5M | -$24.7M | -$29.2M | -$0.78 | – | 10-K filed 25 Mar 2026 |
| FY2024 | 31 Dec 2024 | $69.4M | -$22.2M | -$20.6M | -$0.55 | – | 10-K filed 25 Mar 2026 |
| FY2022 | 31 Dec 2022 | $55.1M | – | – | – | – | 20-F filed 7 Apr 2023 |
| FY2021 | 31 Dec 2021 | $44.1M | – | – | – | – | 20-F filed 8 Apr 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $13.2M | -$14.5M | -$0.39 |
| Q1 FY2026 | 31 Mar 2026 | $17.8M | -$9.1M | -$0.24 |
| Q2 FY2025 | 30 Jun 2025 | $9.5M | -$6.4M | -$0.17 |
| Q1 FY2025 | 31 Mar 2025 | $14.3M | -$7.4M | -$0.20 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| High Intensity Focused Ultrasound (HIFU) | $37.4M | 53.0% |
| DISTRIB Division | $25.7M | 36.5% |
| Lithotripsy (ESWL) | $7.5M | 10.6% |
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Goods | $48.9M | 69.3% |
| Spare parts and services | $11.3M | 16.1% |
| RPPs & leases | $10.3M | 14.6% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $28.5M | 40.4% |
| Asia | $19.6M | 27.7% |
| Other geographical areas | $17.8M | 25.3% |
| France | $4.6M | 6.5% |
Company events
The newest 8-K filings of 13 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 19 Aug 2026 | 8-K | Other events | 8.01, 9.01 |
| 14 Aug 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 13 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 11 Aug 2026 | 8-K | Results, Investor update, Other events | 2.02, 7.01, 8.01, 9.01 |
| 26 Jun 2026 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07, 9.01 |
| 1 Jun 2026 | 8-K | Investor update | 7.01, 9.01 |
| 29 May 2026 | 8-K | Other events | 8.01 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 2 Apr 2026 | 8-K | New debt, Share sale | 2.03, 3.02 |
| 25 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 18 Mar 2026 | 8-K | Investor update | 7.01 |
| 12 Feb 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 385 held.
| Filed | Form | Period |
|---|---|---|
| 15 Sep 2026 | S-8 | – |
| 19 Aug 2026 | 8-K | 14 Aug 2026 |
| 14 Aug 2026 | 10-Q | 30 Jun 2026 |
| 14 Aug 2026 | 8-K | 11 Aug 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 11 Aug 2026 | 8-K | 11 Aug 2026 |
| 26 Jun 2026 | 8-K | 26 Jun 2026 |
| 1 Jun 2026 | 8-K | 1 Jun 2026 |
| 29 May 2026 | 8-K | 29 May 2026 |
| 14 May 2026 | ARS | 31 Dec 2025 |
| 14 May 2026 | DEFA14A | – |
| 14 May 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 14 Aug 2026 | Horn David R., Director | Purchase | 10,000 | $4.75 | $47.5K | 10,000 | 17 Aug 2026 |
| 14 Aug 2026 | Schulz Fran, Director | Purchase | 10,000 | $4.75 | $47.5K | 15,100 | 17 Aug 2026 |
| 14 Aug 2026 | Levine Joshua, Director | Purchase | 10,000 | $4.75 | $47.5K | 45,000 | 17 Aug 2026 |
| 14 Aug 2026 | Mobeck Kenneth S., Chief Financial Officer | Purchase | 5,000 | $4.75 | $23.8K | 181,610 | 17 Aug 2026 |
| 14 Aug 2026 | Willsey Lance, Director | Purchase | 50,000 | $4.75 | $237.5K | 1,291,780 | 17 Aug 2026 |
| 14 Aug 2026 | Rhodes Ryan, Chief Executive Officer | Purchase | 21,000 | $4.75 | $99.8K | 626,649 | 17 Aug 2026 |
| 14 Aug 2026 | Shah Sanket, General Counsel & Corp Sec | Purchase | 5,000 | $4.75 | $23.8K | 72,500 | 17 Aug 2026 |
| 14 Aug 2026 | Annen Steven, SVP, Marketing & Product Mgmt. | Purchase | 5,000 | $4.75 | $23.8K | 136,490 | 17 Aug 2026 |
| 11 May 2026 | Levine Joshua, Director | Purchase | 10,000 | $4.22 | $42.2K | 35,000 | 13 May 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 19 Oct 2026 | Orin Hirschman | 13G | 7.6% | 3.5M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 334.7K | +29.04% | 5.84 |
| 30 Sep 2026 | 259.3K | +5.57% | 2.91 |
| 15 Sep 2026 | 245.7K | -13.67% | 3.1 |
| 31 Aug 2026 | 284.6K | +45.81% | 1.78 |
| 14 Aug 2026 | 195.2K | -23.91% | 1 |
| 31 Jul 2026 | 256.5K | +9.42% | 4.29 |
| 15 Jul 2026 | 234.4K | +23.75% | 5.06 |
| 30 Jun 2026 | 189.4K | +40.37% | 4.03 |
Funds that hold it
From each fund's latest Form 13F.
42 funds held it at 30 Jun 2026: 15 added and 5 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Soleus Capital Management, L.P. | 7,309,254 | $37.9M | 0 |
| Morgan Stanley | 3,336,872 | $17.3M | -8,408 |
| Rock Springs Capital Management LP | 1,386,000 | $7.2M | +8,000 |
| Flax Pond Capital, LLC | 1,525,676 | $6.8M | +742,230 |
| Bruce & Co., Inc. | 438,652 | $2.3M | 0 |
| Parkman Healthcare Partners LLC | 154,832 | $802.0K | 0 |
| Essex Investment Management Co. LLC | 146,005 | $756.3K | +146,005 |
| Cahill Financial Advisors Inc. | 134,960 | $699.1K | 0 |
| US Bancorp | 122,500 | $634.5K | +3,500 |
| UBS Group AG | 118,395 | $613.3K | -51,235 |
Peers
Companies in the same industry.
- Medtronic plc (MDT): revenue $37.5B, market value $123.6B
- LivaNova plc (LIVN): revenue $1.5B, market value $4.3B
- Integer Holdings Corp. (ITGR): revenue $1.8B, market value $4.3B
- Axogen, Inc. (AXGN): revenue $266.9M, market value $2.9B
- TransMedics Group, Inc. (TMDX): revenue $668.5M, market value $2.3B
- Conmed Corp. (CNMD): revenue $1.4B, market value $1.3B
- Ceribell, Inc. (CBLL): revenue $102.0M, market value $1.0B
- CapsoVision, Inc. (CV): revenue $13.9M, market value $341.7M
- Electromed, Inc. (ELMD): revenue $73.8M, market value $225.0M
- Neuraxis, Inc. (NRXS): revenue $5.3M, market value $89.3M